SVA

Sinovac Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.47
0.00
0.00%
Suspension 16:00 04/24 EDT
OPEN
--
PREV CLOSE
6.47
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
6.58
52 WEEK LOW
6.25
MARKET CAP
639.90M
P/E (TTM)
27.35
1D
5D
1M
3M
1Y
5Y

SVA News

More
China's Sinopharm to test potential COVID-19 vaccine in Brazil
Reuters · 07/29 23:06
China's Sinopharm says coronavirus vaccine could be ready by year-end - state media
A coronavirus vaccine candidate developed by China National Pharmaceutical Group (Sinopharm) could be ready for public use by the end of this year, state media reported on Wednesday, ahead of a previous expectation it may become available in 2021. Sinopharm C
Reuters · 07/23 07:07
Bangladesh allows late-stage trial of China's Sinovac COVID-19 vaccine
Bangladesh has approved the third-phase trial of a potential COVID-19 vaccine developed by China's Sinovac Biotech Ltd, officials said on Monday, as infections continue to rise in the densely-populated South Asian country. Sinovac has been looking for volunte
Reuters · 07/20 06:29
Russia may start Phase III trial of COVID-19 vaccine in mid-August - RIA
A Russian institute developing one of the country's potential coronavirus vaccines hopes to start its final stage testing in a small section of the general public in mid-August, the RIA news agency cited the institute's director as saying on Monday. Globally,
Reuters · 07/13 13:56
Thailand plans Nov human testing for potential coronavirus vaccine
Thai researchers plan to begin human trials of a potential vaccine for the new coronavirus in November and are preparing 10,000 doses, a senior official said on Sunday, aiming for a vaccine that could be ready for use by late next year. Following favourable r
Reuters · 07/12 06:14
China's CanSino in talks for COVID vaccine Phase III trial overseas
Chinese vaccine developer CanSino Biologics is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, its co-founder said on Saturday. China's success in driving down COVID-19 infections has made
Reuters · 07/11 13:06
European markets fall as investors look to economic data and U.S. virus surge
European markets retreated Tuesday morning as concerns over the threat to economic recovery of new coronavirus cases in the U.S. temper Monday's rally.
CNBC.com · 07/07 06:20
6 China ETFs From 3 Sectors That Emerged Winners in June
A host of China ETFs outperformed in June. These funds come mainly from the technology, healthcare and clean energy segments.
Zacks · 07/06 18:30

Industry

Pharmaceuticals
-0.28%
Pharmaceuticals & Medical Research
-0.46%

Hot Stocks

Symbol
Price
%Change

About SVA

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
More

Webull offers kinds of Sinovac Biotech Ltd. stock information, including NASDAQ:SVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SVA stock methods without spending real money on the virtual paper trading platform.